Stock Taper
SCREENER COMPARE ANY 2 STOCKS
MGNX
MACROGENICS, INC.
NASDAQ
$4.13
▲ UP 1.23% (0.05)

KEY STATISTICS

Market Cap$262.52 M
52w High$5.08
52w Low$1.29
Dividend Yield—
Frequency—
P/E-3.75
Volume540.92K
Shares Out.63.56M

COMPANY

LEADERSHIP

Eric Blasius Risser
CHIEF EXECUTIVE
Eric Blasius Risser

COMPENSATION 2026

Salary$477,120
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$475,841
Total$952,961

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 10, 2013
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
293

PRICE TARGET

Target High$6.00
Target Low$6.00
Target Median$6.00
Target Consensus$6.00

UPCOMING EARNINGS

DateNov 11, 2026
DayWednesday
Rev. Est.$40.60M
NOV
11
WED

PRICE

$4.13 ▲ UP 1.23% (+$0.05)
$4.00$4.05$4.10$4.159:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM4.13

About MacroGenics, Inc.

http://www.macrogenics.com ↗

MacroGenics, Inc. is a biopharmaceutical company developing antibody-based cancer therapies, including the approved HER2-positive breast cancer drug MARGENZA, with a pipeline targeting solid tumors, hematologic malignancies, HIV, and autoimmune di...

INDUSTRY

Biotechnology

A PRODUCT MACROGENICS, INC. IS KNOWN FOR

lorigerlimab
lorigerlimab

MacroGenics' bispecific DART® molecule targets PD-1 and CTLA-4, is in Phase 2 trials for metastatic prostate and gynecologic cancers, and is its most advanced clinical-stage candidate.

COMPETITORS

COMPETITOR
AZN COMPARE
BMY COMPARE
MRK COMPARE
PFE COMPARE
REGN COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Royalty— — — $255M
Contract Manufacturing$19.84M $11.27M ▼$14.05M ▲—
RevenueFromCollaborativeAgreementsMember$53M — $570K ▼—

ETFS HOLDING THIS STOCK

ETFS HOLDING
60
LISTED HERE
13
RANKED BY POSITION SIZE
VTS.AX
0.00% · 1.9M
XSU.TO
0.01% · 1.5M
FESM
0.02% · 301.6K
SBIO
0.13% · 78.7K
CN
CNCR
3.17% · 71.3K
GSSC
0.02% · 65.5K
ZPRR.DE
0.00% · 61.1K
XRS2.F
0.01% · 57.4K
PRFZ
0.01% · 43.4K
RSSL
0.01% · 29.7K
DCOR
0.00% · 4.0K
URTY
0.00% · 2.6K
AVSC
0.00% · 712

INSTITUTIONAL OWNERSHIP

SHARES OWNED
78.89%
HOLDERS
171
TOP 12 OF 171 · RANKED BY POSITION SIZE
Bellevue Group AG
9.9M sh · $16.67M
Armistice Capital, LLC
6.3M sh · $10.18M
Blackrock Inc.
5.4M sh · $22.96M
Oppenheimerfunds, Inc.
4.5M sh · $80.25M
Vanguard Group Inc
4.2M sh · $6.81M
Bb Biotech AG
3.4M sh · $61.13M
Frazier Life Sciences Management, L.P.
3.2M sh · $5.34M
Renaissance Technologies LLC
3.0M sh · $8.56M
Millennium Management LLC
2.8M sh · $8.08M
Acadian Asset Management LLC
2.5M sh · $7.35M
Two Sigma Investments, LP
2.5M sh · $7.31M
Bank Of America Corp /De/
2.4M sh · $6.94M

RATINGS SNAPSHOT

Overall rating: D+

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score1

INSIDER TRADES

★
OFFICER: SENIOR VP, GC, AND SECRETARY
Peters Jeffrey Stuart
Sale · 31.1K shares
2026-08-19
★
OFFICER: SR VP, RESEARCH & CSO
Bonvini Ezio
Sale · 40.0K shares
2026-08-17
★
OFFICER: SR VP, RESEARCH & CSO
Bonvini Ezio
Purchase · 40.0K shares
2026-08-17
★
DIRECTOR
HEIDEN WILLIAM K
Purchase · 3.8K shares
2026-05-19

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
OVERWEIGHT 1
NEUTRAL 1
3 GRADES IN THE LAST 12 MONTHS
B. Riley Securities BUY Barclays OVERWEIGHT HC Wainwright & Co. NEUTRAL

SECTORS PEERS

PEERPRICE
STTK$7.04COMPARE
OVID$2.80COMPARE
IFRX$2.23COMPARE
ZNTL$3.80COMPARE
WHWK$4.62COMPARE
ORMP$5.03COMPARE
CNTB$2.23COMPARE
COYA$4.59COMPARE